{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:51:46Z","timestamp":1794185506687,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/11\/2023-7142"],"award-info":[{"award-number":["EMDR\/SG\/11\/2023-7142"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.08.013","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T11:14:19Z","timestamp":1726485259000},"page":"e21-e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist"],"prefix":"10.1016","volume":"46","author":[{"given":"Guramrit","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid Ahmad","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0668-8718","authenticated-orcid":false,"given":"Ranju","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.013_bib0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s disease: epidemiology and clinical progression","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0002","first-page":"97","article-title":"Burden of illness in people with Alzheimer\u2019s disease: a systematic review of epidemiology, comorbidities and mortality","volume":"11","author":"Lanct\u00f4t","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0003","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0004","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.3390\/molecules27154839","article-title":"Advances on therapeutic strategies for Alzheimer\u2019s disease: from medicinal plant to nanotechnology","volume":"27","author":"Hassan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0005","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics (review)","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0006","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s43440-021-00310-7","article-title":"Sigma receptors and neurological disorders","volume":"73","author":"Piechal","year":"2021","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0007","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.3390\/ijms24076251","article-title":"Sigma-2 receptors-from basic biology to therapeutic target: a focus on age-related degenerative diseases","volume":"24","author":"Lizama","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0008","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.4103\/1673-5374.259609","article-title":"Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders","volume":"14","author":"Terada","year":"2019","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0009","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the \u03c32 receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/acsmedchemlett.1c00002","article-title":"Sigma-1 and sigma-2 receptor modulators as potential therapeutics for Alzheimer's disease","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0011","doi-asserted-by":"crossref","first-page":"12025","DOI":"10.3390\/ijms241512025","article-title":"The sigma receptors in Alzheimer's disease: new potential targets for diagnosis and therapy","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0012","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.3390\/molecules25225439","article-title":"Sigma-2 receptor-a potential target for cancer\/Alzheimer\u2019s disease treatment via its regulation of cholesterol homeostasis","volume":"25","author":"Yang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jnc.13917","article-title":"Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer\u2019s disease","volume":"140","author":"Yi","year":"2017","journal-title":"J Neurochem"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","article-title":"Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders","volume":"37","author":"Malar","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00401-023-02679-6","article-title":"Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer\u2019s disease","volume":"147","author":"Colom-Cadena","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0016","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s12035-020-01988-1","article-title":"The sigma-2 receptor\/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of A\u03b242 and its protein aggregates","volume":"57","author":"Riad","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0017","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0317-20.2020","article-title":"Proceedings from the fourth international symposium on \u03c3-2 receptors: role in health and disease","volume":"7","author":"Izzo","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life13010001","article-title":"The allosteric antagonist of the sigma-2 receptors\u2014Elayta (CT1812) as a therapeutic candidate for mild to moderate Alzheimer\u2019s disease: a scoping systematic review","volume":"13","author":"Rasheed","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0020","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.3390\/ijms24076251","article-title":"Sigma-2 receptors\u2014from basic biology to therapeutic target: a focus on age-related degenerative diseases","volume":"24","author":"Lizama","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0021","article-title":"Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0022","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug ct1812, an antagonist of the sigma-2 receptor complex for Alzheimer\u2019s disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0023","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/13543784.10.4.593","article-title":"\u03b2-Amyloid therapies in Alzheimer's disease","volume":"10","author":"Jhee","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0024","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0025","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0026","unstructured":"Sigma-2 receptor antagonist 1 | C24H33NO4S | CID 118278088 \u2013 PubChem (nih.gov) [Accessed on 4 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0027","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.3390\/molecules26123743","article-title":"\u03c32 Receptor and its role in cancer with focus on a multitarget directed ligand (MTDL) approach","volume":"26","author":"Abatematteo","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0028","unstructured":"https:\/\/cogrx.com\/about-us\/[Accessed on 19 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (NY)"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0030","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT02570997 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0031","series-title":"Alzheimer's Disease Drug Development: Research and Development Ecosystem","first-page":"135","article-title":"Phase 1 trials in Alzheimer's disease drug development","author":"Windisch","year":"2022"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0032","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jalz.2016.07.127","article-title":"P4-381: a two-part, double-blind, placebo-controlled, phase 1 study of the safety and pharmacokinetics of single and multiple ascending doses of CT1812 in healthy volunteers","volume":"12","author":"Catalano","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0033","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000507569","article-title":"Translational scoring of candidate treatments for Alzheimer's disease: a systematic approach","volume":"49","author":"Cummings","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0034","doi-asserted-by":"crossref","first-page":"P1570","DOI":"10.1016\/j.jalz.2017.07.730","article-title":"[P4\u2013567]: a phase 1 safety trial of the A\u03b2 oligomer receptor antagonist CT1812","volume":"13","author":"Catalano","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0035","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03716427 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0036","unstructured":"https:\/\/cogrx.com\/cognition-therapeutics-reports-drug-drug-interaction-results-for-ct1812-a-disease-modifying-alzheimers-disease-candidate\/[Accessed on 15 March 2023]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0037","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03522129 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0038","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0039","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05225389 [Accessed on 23 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0040","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05248672 [Accessed on 23 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0041","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03507790 [Accessed on 16 Oct. 2023]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0042","unstructured":"https:\/\/cogrx.com\/clinical-trials\/[Accessed on 16 March. 2023]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0043","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04735536 [Accessed on 23 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0044","unstructured":"https:\/\/cogrx.com\/pipeline\/alzheimers-disease-moa\/[Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0045","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05225415 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0046","unstructured":"Study to Evaluate the Safety, Tolerability and efficacy of CT1812 in subjects with mild to moderate dementia with Lewy bodies \u2013 full text view \u2013 ClinicalTrials.gov [Accessed on 11 March 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0047","series-title":"Abstract: 15th conference clinical trials Alzheimer's disease","first-page":"S51","volume":"9","year":"2022"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0048","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05893537 [Accessed on 16 Oct. 2023]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0049","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05531656 [Accessed on 16 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0050","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT02907567 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0051","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jalz.2019.09.072","article-title":"P4-708: clinical biomarker evidence for target engagement, reduction of synaptic damage and disease modification in Alzheimer\u2019s patients treated with Ct1812","volume":"15","author":"Schneider","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0052","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jalz.2018.06.2608","article-title":"S2-02-03: progression of synaptoprotective Sigma-2 antagonists into the clinic","volume":"14","author":"Catalano","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0053","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03493282 [Accessed on 18 Jan. 2024]."},{"key":"10.1016\/j.clinthera.2024.08.013_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/alz.068166","article-title":"CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer\u2019s disease patients from the SPARC clinical trial","volume":"18","author":"Pandey","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2024.08.013_bib0055","unstructured":"Pandey K, Waybright L, Duong DM, et al. CSF proteomics biomarker analysis from the SPARC clinical trial: to assess the effect of the sigma-2 receptor (S2R) modulator CT1812 in Alzheimer's disease patients. Oral presentation at 2022 Alzheimer's Association's International Conference (AAIC); San Diego, CA."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:03:02Z","timestamp":1732410182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002224"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}